Market capitalization | $40.96m |
Enterprise Value | $-6.21m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.95 |
EV/Sales (TTM) EV/Sales | -0.33 |
P/S ratio (TTM) P/S ratio | 2.15 |
P/B ratio (TTM) P/B ratio | 0.86 |
Revenue growth (TTM) Revenue growth | -54.30% |
Revenue (TTM) Revenue | $19.01m |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
3 Analysts have issued a Ocuphire Pharma Inc forecast:
3 Analysts have issued a Ocuphire Pharma Inc forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -9.99 -9.99 |
156%
156%
|
|
Depreciation and Amortization | 0.01 0.01 |
-
|
|
Stock Compensation | 3.51 3.51 |
94%
94%
|
|
Operating Cash Flow | -1.11 -1.11 |
108%
108%
|
|
Investments | - - |
-
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -1.11 -1.11 |
108%
108%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
Head office | United States |
CEO | George Magrath |
Employees | 14 |
Founded | 2018 |
Website | www.ocuphire.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.